Nevo on track for European release after trial posts positive twelve-month data
This article was originally published in Clinica
Executive Summary
The latest results from the RES I trial of Cordis's Nevo drug-eluting stent (DES) indicate that the device is safer than Boston Scientific's Taxus Liberté DES a year after implantation.